Williams, Ryan M. http://orcid.org/0000-0002-2381-8732
Chen, Shi
Langenbacher, Rachel E.
Galassi, Thomas V.
Harvey, Jackson D.
Jena, Prakrit V.
Budhathoki-Uprety, Januka http://orcid.org/0000-0003-3395-4823
Luo, Minkui http://orcid.org/0000-0001-7409-7034
Heller, Daniel A. http://orcid.org/0000-0002-6866-0000
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748, P30-CA008748, R01-CA215719)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM134878, R01GM120570, R01GM096056)
U.S. Department of Health & Human Services | National Institutes of Health (DP2-HD075698)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK114321)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01-NS116353)
Article History
Received: 20 August 2019
Accepted: 6 October 2020
First Online: 7 January 2021
Competing interests
: D.A.H. is a cofounder and officer with equity interest in Goldilocks Therapeutics, Inc., LipidSense, Inc., and Nirova BioSense, Inc. D.A.H. is a member of the scientific advisory boards of Concarlo Holdings, LLC and Nanorobotics, Inc. R.M.W. is a scientific advisor with equity interest in Goldilocks Therapeutics, Inc. M.L. is a member of the scientific advisory board of Epi One, Inc. P.V.J. is a cofounder and officer with equity interest in LipidSense, Inc. and an officer of Nirova BioSense, Inc.